Evolution and cost trends of antihypertensive and hypolipidaemic drug treatment in France
Details
Serval ID
serval:BIB_A2E1F70AEDB6
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Evolution and cost trends of antihypertensive and hypolipidaemic drug treatment in France
Journal
Cardiovascular Drugs and Therapy
ISSN
0920-3206 (Print)
ISSN-L
0920-3206
Publication state
Published
Issued date
2003
Volume
17
Number
2
Pages
175-189
Language
english
Notes
Publication types: Comparative Study ; Journal Article
Publication Status: ppublish
Publication Status: ppublish
Abstract
PURPOSE: To assess the trends of the cost of cardiovascular disease prevention in France for period 1986-1997.
METHODS: MONICA population surveys conducted in two French Regions (Northern and Southwestern France). The individual costs of antihypertensive and hypolipidaemic drug treatment were established in 4765 subjects for the first (1985-1989) and the last (1995-1997) survey taking into account inflation rates and different daily posologies.
RESULTS: After correcting for inflation, minimum and maximum daily cost of antihypertensive treatment remained stable or decreased in both genders. Minimum daily cost for hypolipidaemic drugs remained stable but maximum costs increased considerably in both genders. This was further aggravated by a doubling of the number of subjects under hypolipidaemic drug treatment between both surveys.
CONCLUSIONS: Individual daily cost of antihypertensive treatment has decreased whereas cost of hypolipidaemic treatment has increased during period 1985-1997. The higher number of subjects on hypolipidaemic drug therapy further increased the national expenditure for this class of drugs.
METHODS: MONICA population surveys conducted in two French Regions (Northern and Southwestern France). The individual costs of antihypertensive and hypolipidaemic drug treatment were established in 4765 subjects for the first (1985-1989) and the last (1995-1997) survey taking into account inflation rates and different daily posologies.
RESULTS: After correcting for inflation, minimum and maximum daily cost of antihypertensive treatment remained stable or decreased in both genders. Minimum daily cost for hypolipidaemic drugs remained stable but maximum costs increased considerably in both genders. This was further aggravated by a doubling of the number of subjects under hypolipidaemic drug treatment between both surveys.
CONCLUSIONS: Individual daily cost of antihypertensive treatment has decreased whereas cost of hypolipidaemic treatment has increased during period 1985-1997. The higher number of subjects on hypolipidaemic drug therapy further increased the national expenditure for this class of drugs.
Keywords
Antihypertensive Agents/economics, Antihypertensive Agents/therapeutic use, Cardiovascular Diseases/economics, Cardiovascular Diseases/epidemiology, Cardiovascular Diseases/prevention & control, Hypercholesterolemia/drug therapy, Hypercholesterolemia/economics, Hypercholesterolemia/prevention & control, Hypertension/drug therapy, Hypertension/economics, Hypertension/prevention & control, Hypolipidemic Agents/economics, Hypolipidemic Agents/therapeutic use
Pubmed
Web of science
Create date
01/12/2016 15:01
Last modification date
20/08/2019 15:08